Inovacell K.K. Featured in Nikkei Biotechnology’s “Venture Exploration”
Our company has been highlighted in Nikkei Biotechnology’s “Venture Exploration.” The article provides an in-depth look at our development products, particularly focusing on the progress of our treatment for urge fecal incontinence.
Thomas Östros (EIB) and Ekkehart Steinhuber (Innovacell A.G.)
Innovacell A.G., a 100% subsidiary of Inovacell K.K. (headquartered in Shibuya, Tokyo, CEO: Jason David Sieger), has secured a €15 million credit line from the European Investment Bank (EIB) through a venture debt agreement on March 24.
For more information, visit: EIB Press Release.